Semaglutide 5MG (GLP-1) ANALOGUE

Semaglutide is a man-made analogue of glucagon-like peptide (GLP-1). GLP-1 is a peptide naturally produced in the human body that controls blood sugar levels. It stimulates beta cells in the pancreas to release insulin and suppresses glucagon release from alpha pancreatic cells. Further, it activates GLP-1 receptors in the CNS that result in the feeling of fullness, increased satiety and, in turn, decreased appetite. It also slows down the gastric emptying time, thus preventing the glucose spike after a meal. 

Semaglutide was developed in 2012 by a Danish pharmaceutical company called Novo Nordisk in an attempt to design an analogue of GLP-1 with long life that is resistant to degradation. It has been approved by the FDA for the management of diabetes. On our website, semaglutide for sale is exclusively available for universities and research institutions. 

From Pubchem

Synonyms: Semaglutide, Ozempic, Rybelsus
Molecular Formula: C187H291N45O59
Molecular Weight: 4114 g/mol
CAS Number: 910463-68-2
PubChem CID: 56843331

1.Semaglutide For Weight Loss

There is extensive research on semaglutide for its weight loss effect. A 2018 study looked at the impact of baseline BMI and the occurrence of nausea and vomiting on weight loss induced by semaglutide. The results showed that a higher baseline BMI was associated with greater weight loss, with little to no contribution of nausea or vomiting to this effect. Furthermore, the weight loss effect of semaglutide was far greater than comparators (who either receive a placebo or other GLP-1 agonists) regardless of basal BMI[1].

In a later study, it was shown that semaglutide was well tolerated for over 52 weeks, with the most common side effect observed being nausea. Further, in combination with lifestyle and diet, this drug showed greater weight loss as compared to placebo [2]. Similarly, another study found that overweight or obese adults who completed a 20-week run-in period and continued their treatment with semaglutide experienced ongoing weight loss as compared to those who took placebo [3].

A literature review article published in 2023 summarized the results of three clinical trials (SUSTAIN, PIONEER and STEP) on the weight loss effect of semaglutide. It concluded that the semaglutide (oral or injectable) has greater efficacy in terms of weight loss as compared to placebo and other medications, which led to the approval of the FDA of semaglutide for weight loss [4]. 

2. Semaglutide and Diabetes

Semaglutide for diabetes has already been approved by FDA after a series of successful trials called SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes). The SUSTAIN trials have helped establish effective semaglutide dosage. However, these trials are still ongoing and currently, semaglutide is in phase 3.

The latest SUSTAIN trial was published in 2022 that showed semaglutide once a week led to greater HBA1C reduction as compared to insulin aspart thrice per day. Furthermore, individuals taking semaglutide experienced greater weight loss as compared to those who took insulin aspart[5]. 

3. Current Status of Semaglutide

Currently, two phase-three clinical trials are being carried out to examine the efficacy of semaglutide in early Alzheimer's disease, named as Evoke trial and Evoke plus trial[6]. Moreover, SOUL and SELECT trials are being carried out to assess the cardiovascular outcomes in patients with type 2 diabetes taking semaglutide [7, 8]. Semaglutide for sale at our website is restricted to educational and research purposes, only buy semaglutide if you are a researcher.

1. Ahrén, B., et al., Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018. 20(9): p. 2210-2219.
2. Gao, X., et al., Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 2022. 13.
3. Rubino, D., et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. 325(14): p. 1414-1425.
4. Singh, G., M. Krauthamer, and M. Bjalme-Evans, Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. Journal of Investigative Medicine, 2022. 70(1): p. 5-13.
5. Kellerer, M., et al., Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab, 2022. 24(9): p. 1788-1799.
6. Atri, A., et al., evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease. Alzheimer's & Dementia, 2022. 18(S10): p. E062415. 
7. McGuire, D.K., et al., Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes, Obesity and Metabolism, 2023. 25(7): p. 1932-1941.
8. Ryan, D.H., et al., Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J, 2020. 229: p.61-69.